Laurion Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Laurion Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-290,850	Closed	-$10.8M	–	345
2024 Q2	$10.8M	Buy	290,850 +42,032	+17%	+$1.59M	0.13%	107
2024 Q1	$10.4M	Buy	248,818 +110,287	+80%	+$4.53M	0.09%	186
2023 Q4	$5.49M	Buy	+138,531	New	+$4.07M	0.05%	237
2016 Q3	–	Sell	-987	Closed	-$65K	–	929
2016 Q2	$65K	Buy	+987	New	+$62.7K	﹤0.01%	784
2015 Q3	–	Sell	-660	Closed	-$250K	–	745
2015 Q2	$250K	Buy	+660	New	+$262K	﹤0.01%	545
2014 Q4	–	Sell	-1,127	Closed	-$219K	–	323
2014 Q3	$219K	Buy	+1,127	New	+$246K	﹤0.01%	256

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Laurion Capital Management's CLDX Position: Q3 2024 in Review

Laurion Capital Management sold out of Celldex Therapeutics (CLDX) in Q3 2024, closing a stake of 290,850 shares — an estimated $10.8M sold.

Laurion Capital Management first reported a position in CLDX in Q3 2014 and held it in 6 quarters. The position peaked at $10.8M in Q2 2024. 176 funds tracked by Wall St. Rank hold CLDX as of Q3 2024.

Laurion Capital Management reported no remaining Celldex Therapeutics position as of Q3 2024 after selling out during the quarter.
Laurion Capital Management sold 290,850 Celldex Therapeutics shares in Q3 2024, an estimated $10.8M.
Laurion Capital Management first reported a position in Celldex Therapeutics in Q3 2014 and held it in 6 quarters.
Laurion Capital Management's Celldex Therapeutics position peaked at $10.8M in Q2 2024.
176 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2024.

Based on Laurion Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.